# FDA Inspection 1118260 - National Cancer Institute, Cancer Therapy Evaluation Program - January 10, 2020

Source: https://www.globalkeysolutions.net/records/fda_inspections/national-cancer-institute-cancer-therapy-evaluation-program/152369c6-484d-474f-982c-e01e5775d199
Source feed: FDA_Inspections

> FDA Inspection 1118260 for National Cancer Institute, Cancer Therapy Evaluation Program on January 10, 2020. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1118260
- Company Name: National Cancer Institute, Cancer Therapy Evaluation Program
- Inspection Date: 2020-01-10
- Classification: No Action Indicated (NAI)
- Project Area: Bioresearch Monitoring
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 891981 - 2014-07-17](https://www.globalkeysolutions.net/records/fda_inspections/national-cancer-institute-cancer-therapy-evaluation-program/3b211a2b-f2f0-4ba6-abdf-e658b694e7ce)

Company: https://www.globalkeysolutions.net/companies/national-cancer-institute-cancer-therapy-evaluation-program/8cc7f4d2-3770-43d0-adba-33439499bb74

Office: https://www.globalkeysolutions.net/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c